Updated:
Joinn Laboratories (China)
Joinn Laboratories (China) is a corporate investor based in Beijing, China. It manages $1.4 billion in assets across two funds, primarily focused on Asia.
Joinn Laboratories (China)
Joinn Laboratories (China) is a corporate investor based in Beijing, China. It manages $1.4 billion in assets across two funds, primarily focused on Asia.
General information
Firm type
Corporate Investor
Year founded
1995
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
No. 5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, China
Additional offices
Suzhou, Jiangsu Province, China · Northern California, USA · Wuzhou, Guangxi, China
Principals
Feng Yuxia
Chairperson
Zhou Zhiwen
Co-founder
Sector focus
Frequently asked questions
Who controls Joinn Laboratories?
Feng Yuxia co-founded the firm in 1995 and remains chairperson and controlling shareholder. Her spouse Zhou Zhiwen is also a co-founder. The founders' son, Zhou Fengyuan, owns Biorichland, a related-party real estate entity that leases facilities back to Joinn.
What makes Joinn's investment model structurally different from other CROs?
Joinn owns and operates captive non-human primate breeding colonies across multiple sites in southern China. During periods of global NHP supply tightness, this gives Joinn a cost and availability advantage in preclinical studies and allows the firm to invest directly in drug-development programs while underwriting the service revenue.
Does Joinn Laboratories invest directly in biotech companies?
Yes. Joinn acts as a corporate investor that takes direct equity stakes in early-stage biotech and pharmaceutical programs, often alongside its preclinical service agreements. The firm has publicly documented a co-investment relationship with Nexelis for bioanalytical studies servicing clinical trials in China.
Where does Joinn derive its biologic assets?
Joinn maintains dedicated non-human primate breeding bases in Wuzhou (Guangxi Zhuang Autonomous Region), Yunnan, and Nanning. These captive colonies supply the firm's preclinical toxicology and pharmacology operations and function as a strategic asset held on its balance sheet.
Does Joinn maintain operations outside of China?
The firm owns a commercial research property in Northern California, which extends its preclinical toxicology capabilities internationally and offers a regulatory foothold for clients pursuing FDA submissions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: